Orphic Therapeutics, Inc. logo

Orphic Therapeutics, Inc.

OrPhi Therapeutics Inc., is researching a therapy that would treat a blood disorder, cerebral amyloid angiopathy or _CAA,” which can cause strokes They are also involved in researching a genetic form of the disease GM2 gangliosidoses.

Founded by John W Steele IV IRACDA a postdoctoral fellow at UC San Diego with the idea of commercializing its various researches on Alzheimers disease, proteinopathies, and neurodegeneration.In support of Carlsbad Life Science Incubator.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://orphictherapeutics.com
Founded2014
Disease Focus
Development Stage
STOCK CODENon Listed
Address
2351 Faraday Ave, CA, 92008-7216
Carlsbad
United States
Email
Contact Number
+1 760-814-1149

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/orphic-therapeutics” connections=”true” suffix=””]

OrPhis Chaperone based approach acts upstream of the immunotherapies by preventing the formation of toxic A_ oligomers inside neurons without altering normal A_ processing and function.

In Sep 2017, Orphi Therapeutics was awarded $860K SBIR phase 2 grant.

In 2015, Orphi Therapeutics was awarded with two SBIR phase 1 grants, first of $ 225,000 to a study for Alzhiemers Disease and the other worth $ 150,000, for GM2 Gangliosidoses.